Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF-Reference-Cited by-同舟云学术

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Published:2024-03-12 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Žáčková Daniela^ORCID,Semerád Lukáš,Faber Edgar,Klamová Hana,Stejskal Lukáš,Bělohlávková Petra,Karas Michal,Cmunt Eduard,Černá Olga,Procházková Jiřina,Čičátková Petra,Kvetková Anežka,Horňák Tomáš^ORCID,Skoumalová Ivana,Srbová Dana,Šálek Cyril^ORCID,Buffa David,Voglová Jaroslava,Jurček Tomáš,Folta Adam,Ježíšková Ivana,Žižková Hana,Machová Poláková Kateřina,Papajík Tomáš,Žák Pavel,Jindra Pavel^ORCID,Svobodník Adam,Štěpánová Radka,Mayer Jiří^ORCID

Funder

Ministerstvo Zdravotnictví Ceské Republiky

Ministry of Health of the Czech Republic – Conceptual Development of Research Organization

National budget through MAYS, LRI CZECRIN

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02215-9.pdf

Reference15 articles.

1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

2. Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102–12.

3. Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21:e241–9.

4. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055–9.

5. Jiang Q, Liu ZC, Zhang SX, Gale RP. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142:1539–47.